The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
-
Research Site, Phoenix, Arizona, United States, 85054
Research Site, Los Angeles, California, United States, 90095
Research Site, San Francisco, California, United States, 94115
Research Site, San Francisco, California, United States, 94143
Research Site, New Haven, Connecticut, United States, 06519
Research Site, Jacksonville, Florida, United States, 32224
Research Site, Tampa, Florida, United States, 33606
Research Site, Atlanta, Georgia, United States, 30322
Research Site, Chicago, Illinois, United States, 60608
Research Site, Chicago, Illinois, United States, 60637
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Alexion Pharmaceuticals, Inc.,
2028-11-21